Proteomics studies benefit from the use of multiplex biomarkers panels. This results in better and faster results for protein biomarker research. Identifying a signature from multiple proteins is more relevant than looking at a single protein. Using high-multiplex immunoassays is a method to create and utilize proteomics panels. However, classical multiplex assays can compromise data quality due to cross-reactivity issues. The SnapChip technology from ParallexBio addresses these issues. If you are involved with protein biomarkers panels development, you will likely benefit from this innovative technology.
Problem with Sandwich ELISA
For High multiplex assay for protein biomarkers panels, the sandwich immunoassay is a powerful technique to measure multiple protein concentrations simultaneously. Its wide adoption is hampered by inadequate antibody specificity which results in cross-reactivity and false positive signals This is a known weakness of multiplexed assays that is mitigated by months of assay optimization and validation, and despite considerable effort, it’s often impossible to combine related analytes in the same assay.
Parallex BioAssays Inc. substituted the “detection soup” by an array of detection nanodroplets and offers a new microarray-to-microarray approach to deliver the detection antibodies precisely to their cognate spots. As a result, a cross-reaction free chip harboring an assembly of parallelized assays, physically isolated from each other. The resulting protein biomarkers panels will produce the best possible data.
As an example protein biomarkers panel, SnapChipTM technology was used to measure key proteins and PTM in the Akt pathway. The colocalization of the capture and detection antibodies allows to mix-and-match any existing singleplex. Indeed, the analysis of the 3 Akt isoforms in the same assay is not possible with other multiplex technologies because of cross-reactions and a lack of specificity of the antibodies. On the SnapChipTM, the assays are contained in nanodroplets and are physically isolated, which opens new opportunities and eliminates the risk of false positives. Other multiplex biomarkers panels are available, and customized chips can be rapidly developed.
See below for a short video illustrating how the SnapChip technology is used. It shows how the two microarrays are overlapped using the SnapChip device.